357263-13-9

Usage

Uses

Used in Pharmaceutical Industry:
SINOVA SL-02580 is used as a pharmaceutical excipient for its humectant properties, which helps in stabilizing the moisture content in medications and improving their shelf life.
Used in Cosmetics Industry:
SINOVA SL-02580 is used as a humectant and solvent in the cosmetics industry, providing moisturizing and skin-conditioning benefits to various cosmetic products.
Used in Food Industry:
SINOVA SL-02580 is used as a humectant, emulsifier, and sweetener in the food industry, enhancing the texture, taste, and shelf life of various food products.
Used in Personal Care Industry:
SINOVA SL-02580 is used as a humectant and moisturizer in personal care products, such as lotions, creams, and shampoos, providing hydration and improving skin and hair health.
Used in Industrial Applications:
SINOVA SL-02580 is used as a solvent, humectant, and heat transfer medium in various industrial applications, such as in the manufacturing of resins, inks, and dyes.
Used in Energy Industry:
SINOVA SL-02580 is used as a component in the production of biodiesel and as a de-icing agent in the energy industry, contributing to the development of sustainable and eco-friendly energy solutions.
Used in Agricultural Industry:
SINOVA SL-02580 is used as a humectant and fertilizer additive in the agricultural industry, improving the water retention capacity of soil and promoting plant growth.

references

[1] wang t1, zhang z, wallace ob, deshpande m, fang h, yang z, zadjura lm, tweedie dl, huang s, zhao f, ranadive s, robinson bs, gong yf, ricarrdi k, spicer tp, deminie c, rose r, wang hg, blair ws, shi py, lin pf, colonno rj, meanwell na. discovery of 4-benzoyl-1-[(4-methoxy-1h- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (r)-methylpiperazine (bms-378806): a novel hiv-1 attachment inhibitor that interferes with cd4-gp120 interactions. j med chem. 2003 sep 25;46(20):4236-9.

InChI:InChI=1/C22H22N4O4/c1-14-13-25(21(28)15-6-4-3-5-7-15)10-11-26(14)22(29)19(27)16-12-24-20-18(16)17(30-2)8-9-23-20/h3-9,12,14H,10-11,13H2,1-2H3,(H,23,24)/t14-/m1/s1

Upstream product

• 357262-90-9 4-benzoyl-2-(R)-methyl-1-[(7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357262-60-3 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione 
• 357263-39-9 1-benzoyl-3-(R)-methylpiperazine 
• 357263-49-1 methyl α-oxo-1H-pyrrolo[2,3-b]pyridine-3-acetate 
• 75336-86-6 (2R)-methylpiperazine 
• 271-63-6 7-Azaindole 
• 93-58-3 benzoic acid methyl ester 
• 357262-96-5 4-benzoyl-2-(R)-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357263-05-9 4-benzoyl-1-[(4-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 

Downstream Products

• 357263-31-1 (R)-N-(benzoyl)-3-methyl-N'-[(4-hydroxyl-7-azaindol-3-yl)-oxoacetyl]-piperazine 

Relevant academic research and scientific papers

Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120

This paper describes selected modification and structure-activity relationship of the small molecule HIV-1 inhibitor, 4-benzoyl-1 -[(4-methoxy-1-H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806). The results revealed: i) that both the presence and configuration (R vs. S) of the 3-methyl group on the piperazine moiety are important for the antiviral activity, with the 3-(R)-methyl derivatives showing the highest activity; ii) that the electronegativity of the C-4 substituent on the indole or azaindole ring seems to be important for the activity, with a small, electron-donating group such as a fluoro or a methoxy group showing enhanced activity, while a nitro group diminishes the activity; iii) that the N-1 position of the indole ring is not eligible for modification without losing activity; and iv) that bulky groups around the C-4 position of the indole or azaindole ring diminish the activity, probably due to steric hindrance in the binding. We found that a synthetic bivalent compound with two BMS-378806 moieties being tethered by a spacer demonstrated about 5-fold enhanced activity in an nM range against HIV-1 infection than the corresponding monomeric inhibitor. But the polyacrylamide-based polyvalent compounds did not show inhibitory activity at up to 200 nM. The Royal Society of Chemistry 2005.

Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution formulation. However, aqueous suspensions of 2 were poorly bioavailable, indicative of dissolution-limited absorption. The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.

Antiviral azaindole derivatives

The present invention is directed to a series of chemical entities that express HIV-1 inhibitory activities.

Antiviral azaindole derivatives

The present invention is directed to a series of chemical entities that express HIV-1 inhibitory activities.